Skip to main content
TipRanks
Go Ultimate75% OFF

Indo US Bio-Tech Ltd. (INDOUS) AI Stock Analysis

0 Followers
IN:INDOUS

Indo US Bio-Tech Ltd.

(NSE:INDOUS)

Select Model
Rating:59Neutral
Price Target:INR 69.00â–²(5.73% Upside)
Action:reiterated
Date:10/30/26

The overall score reflects a fundamentally mixed profile anchored by an attractive P/E valuation and solid revenue growth, but heavily penalized by aggressive cash burn and deeply negative free cash flow. While the stock has seen short-term price stabilization, broader technical indicators highlight an ongoing long-term downtrend, making reversing the severe cash flow deterioration critical for sustained upside.

Positive Factors
Strong Revenue GrowthFY2026 revenue growth of 71.94% indicates strong recent demand or product-volume expansion across the seed portfolio. If sustained, this scale can improve channel reach and support investment in breeding, processing, and marketing, strengthening the platform over coming quarters.
Negative Factors
Negative Cash GenerationNegative operating and free cash flow show that reported earnings were not converted into cash during FY2026. Persistent weak conversion can constrain reinvestment, increase reliance on external funding, and make the business more vulnerable if working-capital needs remain elevated.

Indo US Bio-Tech Ltd. (INDOUS) vs. iShares MSCI India ETF (INDA)

-60%-40%-20%0%20%40%IN:INDOUS-46.29%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.59B
Dividend Yield
―
Average Volume (3M)
2,456
Price to Earnings (P/E)
30.8
Beta (1Y)
0.74
Revenue Growth
-18.31%
EPS Growth
-74.34%
Country
India
Employees
883
Sector
General
Sector Strength
55
Industry
Agricultural Inputs

Indo US Bio-Tech Ltd. Business Overview & Revenue Model

Company Description

Indo Us Bio-Tech Ltd. is an Indian firm specializing in the entire seed value chain, encompassing production, processing, packaging, and distribution across India. Their diverse product lineup features an extensive selection of vegetable seeds, inclu...

How the Company Makes Money

Indo US Bio-Tech Ltd. primarily makes money by selling agricultural seeds to farmers, distributors, and other agri-channel partners. Its main revenue stream is the sale of seeds produced through its integrated pipeline: (1) developing seed varieties/...

Indo US Bio-Tech Ltd. Financial Statement Overview

Summary

Financial performance is highly polarized. The company displays strong revenue growth, improved operating margins, and a well-capitalized balance sheet with manageable debt. However, this is heavily offset by a severe operational cash outflow and deep negative free cash flow, raising significant concerns over earnings quality and working capital management.

Income Statement

75Positive

Balance Sheet

78Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024
Income Statement
Total Revenue642.31M1.10B1.04B
Gross Profit143.60M301.69M294.70M
EBITDA88.39M170.66M13.08M
Net Income71.37M131.23M162.67M
Balance Sheet
Total Assets1.17B1.33B978.43M
Cash, Cash Equivalents and Short-Term Investments5.88M69.13M2.48M
Total Debt276.43M370.36M148.36M
Total Liabilities305.44M405.63M193.24M
Stockholders Equity866.69M925.34M785.18M
Cash Flow
Free Cash Flow-83.36M-149.89M-100.69K
Operating Cash Flow-74.56M-125.81M91
Investing Cash Flow-34.90M-15.00M-7.92M
Financing Cash Flow104.92M199.56M-14.77M

Indo US Bio-Tech Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price65.26

Price Trends

50DMA73.70Negative
100DMA79.29Negative
200DMA95.18Negative

Market Momentum

MACD-2.51Positive
RSI43.16Neutral
STOCH27.30Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDOUS, the sentiment is Negative. The current price of 65.26 is below the 20-day moving average (MA) of 68.80, below the 50-day MA of 73.70, and below the 200-day MA of 95.18, indicating a bearish trend. The MACD of -2.51 indicates Positive momentum. The RSI at 43.16 is Neutral, neither overbought nor oversold. The STOCH value of 27.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDOUS.

Indo US Bio-Tech Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:INDOUS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:NATHBIOGENIN:NATHBIOGEN66NeutralINR 2.59B7.39―1.47%16.89%-21.43%
IN:INDOUSIN:INDOUS59NeutralINR 1.31B30.79――-18.31%-74.34%
IN:IGCLIN:IGCL56NeutralINR 3.81B8.28――――
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:IPLIN:IPL51NeutralINR 13.55B14.29―0.64%2.89%-9.47%
IN:BESTAGROIN:BESTAGRO43NeutralINR 5.19B10.82―0.68%-19.67%275.98%
IN:ASTECIN:ASTEC42NeutralINR 12.35B-15.50――16.06%36.97%

* General Sector Average

Performance Comparison

-50%-25%0%25%50%IN:INDOUSIN:ASTECIN:BESTAGROIN:IPLIN:NATHBIOGENIN:IGCLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:INDOUS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:INDOUSIndo US Bio-Tech Ltd.65.26-58.79-47.39%
IN:ASTECAstec Lifesciences Limited558.25-68.00-10.86%
IN:BESTAGROBest Agrolife Ltd.14.60-5.31-26.65%
IN:IPLIndia Pesticides Ltd.116.80-59.95-33.92%
IN:NATHBIOGENNath Bio-Genes (India) Ltd.135.00-23.50-14.83%
IN:IGCLIndogulf Cropsciences Limited56.64-40.91-41.94%

Indo US Bio-Tech Ltd. Corporate Events

Indo US Bio-Tech Sets Virtual Date for 22nd Annual General Meeting

Sep 6, 2026

Indo US Bio-Tech Ltd. has announced that its 22nd Annual General Meeting will be held on September 30, 2026 at 2:30 p.m. via video conferencing and other audio-visual means, in line with recent circulars issued by the Ministry of Corporate Affairs an...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026